Arizona Pharmacy Flash
Dec. 25, 2012

Telaprevir linked to potentially fatal skin reaction
The label for the hepatitis C drug telaprevir now features a boxed warning on the risk for serious and sometimes fatal skin reactions, the Food and Drug Administration recently announced. Patients must stop taking telaprevir along with its partner drugs peginterferon and ribavirin if they experience a serious skin reaction, particularly a rash with systemic symptoms, or a progressive severe rash, according to the label change that the FDA approved on Dec. 14. More

PQA January Quality Forum Lecture Series
Successful transitioning from hospital to community: Exploring the pharmacist's role in an open healthcare system. Learn more. More

Register today for the AzPA Psychiatric Certificate Program
Assessing, Monitoring, and Managing Patients with Psychiatric Disorders: Comprehensive Medication Therapy Management to Optimize Pharmaceutical Care Learn more.

Inaugural Southwest Pharmacy Symposium
Become a Pharmacy A.C.E. — Advocate, Communicate, Educate. Saturday, Jan. 26, 2013. Learn more.

Shop and support AzPA
Will you be shopping online at this holiday season? Bookmark the AzPA Amazon Affiliates page, and a portion of your purchases will be donated to AzPA.More

Holiday shopping is upon us
Remember to purchase your gift cards through AzPA and support pharmacy education in Arizona. Learn more.

Not an AzPA member? Join today
Not an AzPA member? Join the only statewide association representing all pharmacy professionals in all pharmacy practice settings. With over 1,500 members, we are a leading association of pharmacists spreading the news and events of our industry.More

Pharmacy compounding primer for physicians: Prescriber beware
Since the development of federal standards for drug approval, the practice of medicine has historically involved the compounding of medications based on a physician's determination that a Food and Drug Administration-approved product either did not exist or could not be used for medical reasons. Today, prescriptions for non-FDA-approved compounded drugs may be driven by fanciful and largely unregulated pharmacy advertisements to physicians and patients and/or payer reimbursement policies, thus placing prescribers in the backseat for clinical decision making. This article outlines essential differences between FDA-approved drugs and compounded drugs and reasserts the primary medical role of physicians for determining what medical circumstances may necessitate treatment with non-FDA-approved products.More

10 essential pharmacy apps
Pharmacy Times
The December holidays are upon us and with them the chance of receiving a new smartphone, tablet or other mobile device as a gift. Whether you're expecting a new tech toy this year or simply looking to add some new resources to your existing device, the following apps can help enhance your pharmacy practice.More

Survey: Kroger pharmacy tops in customer service
Consumer Affairs
Does the convenience of being able to pick up your medication along with the other items you need, worth sacrificing the personal level of customer service that you're likely to get at a small neighborhood pharmacy? According to a Canadian research company that surveyed 1,500 U.S. consumers on this subject, customer service is most important to people, and even though large chains may not compare to mom and pop pharmacies in this area, some of them provide better customer service than others. The results of the survey showed that Kroger ranked the highest in a number of customer service categories compared to other pharmacy chains both big and small.More

Cancer beats all other fields for new drug approvals in 2012
Eleven new drugs for the treatment of cancer were approved by the Food and Drug Administration in 2012. Only a few of these agents have been approved in Europe; most are still under review there. "This is more than any other therapeutic category," Stephanie Yao, from the FDA Office of Public Affairs, told Medscape Medical News. So far this year, the FDA has approved 34 new molecular entities and new biologic agents this year, 11 of which were oncology drugs, she explained. And Yao pointed out that there are still two weeks left in this calendar year. More

Leading change in the pharmacy profession
The St. Louis American
Lakesha Butler, clinical associate professor in the School of Pharmacy at Southern Illinois University Edwardsville, is passionate about improving the level of patient care for underrepresented minorities. It is one reason that she was an excellent candidate to participate in the St. Louis Business Diversity Initiative Fellows Program, according to Dr. Gireesh Gupchup, dean of SIUE's School of Pharmacy. Butler is one of 66 people, representing 39 organizations in the bistate area, who were chosen to participate in the yearlong program, said Valerie Patton, vice president of Economic Inclusion for the St. Louis Regional Chamber and Growth Association and executive director of the St. Louis Business Diversity Initiative.More

Is dexmedetomidine more cost-effective than propofol?
Pharmacy Practice News
Dexmedetomidine is a more cost-effective option than propofol for sedating mechanically ventilated patients after cardiovascular surgery, according to a single-institution, retrospective study. "Patients got off the ventilator quicker with dexmedetomidine," said Matthew Wanat, PharmD, a clinical assistant professor at the University of Houston College of Pharmacy, and a clinical specialist at The Methodist Hospital in Houston.More

Attorney: Dozens sue pharmacy but compensation uncertain
Insurance Journal
Dennis O'Brien rubs his head as he details ailments triggered by the fungal meningitis he developed after a series of steroid shots in his neck: nausea, vomiting, dizziness, drowsiness, blurred vision, exhaustion and trouble with his speech and attention. He estimates the disease has cost him and his wife thousands of dollars in out-of-pocket expenses and her lost wages, including time spent on six hour round trip weekly visits to the hospital. They've filed a lawsuit seeking $4 million in damages from the Massachusetts pharmacy that supplied the steroid injections, but it could take years for them to get any money back and they may never get enough to cover their expenses.More

Drugs hold promise for severe juvenile arthritis patients
HealthDay News
Children who suffer from a rare and painful form of arthritis that's accompanied by fever and rashes may soon have more treatment options. Two studies published in the Dec. 20 issue of the New England Journal of Medicine suggest that two drugs — canakinumab and tocilizumab — reduce symptoms, including severe joint pain experienced by children with systemic juvenile idiopathic arthritis.More

FDA panel considers 1st drug for chronic fatigue syndrome
HealthDay News
A Food and Drug Administration advisory committee met Dec. 20 to consider approval of the first drug to treat chronic fatigue syndrome. The experts discussed the risks and benefits associated with the intravenous drug rintatolimod. The drug's maker, Hemispherx Biopharma of Philadelphia, failed to win the FDA's OK in 2009 because of concerns about study methodology.More